Injective Price Prediction: INJ Surges 33% as Bulls Eye $6

Injective extended its recovery rally this week after buyers pushed the token above several major resistance levels. The asset climbed more than 8% in the past 24 hours and gained over 33% during the last seven days. 

Trading activity also accelerated sharply, with daily volume surpassing $233 million. Consequently, market sentiment around INJ has shifted bullish again after months of weak momentum.

On the 4-hour chart, INJ continues to print higher highs and higher lows. Moreover, the token now trades above all major exponential moving averages. That structure confirms a strong continuation trend after the recent breakout above the key Fibonacci resistance near $4.71.

Momentum currently targets the psychological $5.20 zone. Traders now view that region as the most important short-term breakout level. A confirmed close above it could open the door toward $5.50 and potentially the $6.00 region.

Injective’s bullish momentum continues to strengthen as buyers defend every short-term pullback. Additionally, the 20 EMA remains well above the 50 EMA, while the 100 EMA continues trending upward. That alignment often signals sustained directional strength.

However, technical indicators also suggest caution. The stochastic RSI now approaches overbought territory near the 80 level. Hence, the market could enter a consolidation phase before attempting another breakout.

If buyers maintain control above $4.71, bullish continuation remains likely. Furthermore, the 20 EMA near $4.59 now acts as immediate dynamic support. A deeper correction could test the broader support range between $4.32 and $4.04.

Still, the wider structure remains constructive unless INJ loses the macro trend zone near $3.77. Until then, traders may continue viewing dips as temporary pullbacks within a larger uptrend.

Derivatives activity also reflects improving confidence after months of contraction. Injective’s open interest previously exceeded $200 million during late-2025 bullish conditions before collapsing below $60 million earlier this year.

Recent data now shows open interest rebounding toward $85 million. Although the recovery remains modest, the increase suggests traders are gradually rebuilding leveraged exposure instead of aggressively exiting positions.

Spot market flows also reveal improving sentiment. Earlier sessions recorded persistent exchange outflows as INJ declined from higher price levels. 

However, fresh inflows recently returned, including a positive netflow reading near $1.42 million. Consequently, weakening sell pressure now supports the ongoing recovery structure.

Beyond technical strength, Injective continues expanding its institutional footprint. The network recently emerged as the default USDC denomination within the Cosmos ecosystem after Noble shifted focus toward its independent EVM chain.

The integration introduces one-signature cross-chain transfers, near-zero gas fees, and sub-second settlement support through CCTP infrastructure. Significantly, the agreement remains locked for at least four years, with dYdX positioned as the first rollout partner.

Institutional visibility also increased after Bitnomial launched regulated INJ futures in the United States. Shortly afterward, Kraken acquired Bitnomial in a $550 million deal, potentially strengthening INJ’s access to institutional trading infrastructure.

Key levels remain clearly defined as Injective continues trading inside a strong bullish continuation structure following its breakout above major resistance zones.

Upside levels: $5.20 remains the immediate breakout barrier, followed by $5.50 and the broader $5.90–$6.20 expansion zone. A confirmed breakout above $5.20 could accelerate bullish momentum and trigger another leg higher as traders chase continuation strength.

Downside levels: $4.71 now serves as the first major support after the recent Fibonacci breakout. Below that, the 20 EMA near $4.59 acts as dynamic support, followed by the broader $4.32–$4.04 demand zone. Macro trend support remains positioned near $3.77.

Resistance ceiling: The $5.20 psychological barrier remains the key level bulls must flip into support to maintain momentum dominance in the near term.

The technical structure suggests INJ remains in a momentum-driven expansion phase after reclaiming all major EMAs and establishing higher highs and higher lows since April. However, Stochastic RSI conditions near overbought territory also signal rising short-term cooling risk as price stretches away from moving averages.

Injective price prediction now depends heavily on whether buyers can maintain control above the $4.71 breakout zone while pushing through the critical $5.20 resistance area. Continued growth in trading activity, recovering open interest, and improving spot inflows support the bullish case.

Additionally, institutional developments surrounding regulated INJ futures and Injective’s growing role in Cosmos stablecoin infrastructure continue strengthening long-term sentiment.

If momentum remains strong, INJ could extend toward $5.50 and potentially retest the $6 region in the coming sessions. However, failure to defend $4.71 may trigger short-term profit-taking toward $4.59 and lower support areas before buyers attempt another breakout. For now, INJ remains firmly positioned inside a bullish recovery structure, with volatility expected to increase near resistance.